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Abstract
Suppressor of Lin-12-like (C. elegans) (SEL1L) participates in the endoplasmic reticulum-associated protein deg-
radation pathway, malignant transformation and stem cell biology. We explored the role of SEL1L in 110 adult
gliomas, of different molecular subtype and grade, in relation to cell proliferation, stemness, glioma-associated
microglia/macrophages (GAMs), prognostic markers and clinical outcome. SEL1L protein expression was assessed
by immunohistochemistry and Western blotting. Genetic and epigenetic alterations were detected by molecular
genetics techniques. SEL1L was overexpressed in anaplastic gliomas (World Health Organization [WHO] grade III)
and in glioblastoma (GB, WHO grade IV) with the highest labelling index (LI) in the latter. Immunoreactivity was
significantly associated with histological grade (p = 0.002) and cell proliferation index Ki-67/MIB-1
(p = 0.0001). In GB, SEL1L co-localised with stemness markers Nestin and Sox2. Endothelial cells and vascular
pericytes of proliferative tumour blood vessels expressed SEL1L suggesting a role in tumour neo-vasculature.
GAMs consistently expressed SEL1L. SEL1L overexpression was significantly associated with TERT promoter
mutations (p = 0.0001), EGFR gene amplification (p = 0.0013), LOH on 10q (p = 0.0012) but was mutually
exclusive with IDH1/2 mutations (p = 0.0001). SEL1L immunoreactivity correlated with tumour progression and
cell proliferation, conditioning poor patient survival and response to therapy. This study emphasises SEL1L as a
potential biomarker for the most common subgroup of TERT mutant/EGFR amplified/IDH-WT GBs.
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Introduction
Gliomas are the most common primary tumours of the
central nervous system (CNS). According to the
revised 2016 World Health Organization (WHO) clas-
sification of CNS tumours, they are classified into
genetically and histologically identified entities and
variants [1]. Glioblastoma (GB) is the most aggressive
tumour in adults, characterised by genotypic and phe-
notypic heterogeneity and by resistance to therapy.
Despite major advances in treatment modalities, the
prognosis of malignant gliomas remains dismal. GB
has a median overall survival (OS) of 6 months after
surgery, 12.1 months after radiotherapy (RT) and
14.6 months after RT plus concomitant and adjuvant
chemotherapy (CHT) with temozolomide (TMZ) [2].
The identification of new biomarkers involved in
malignant transformation would be useful to improve
diagnosis, prognosis and response to treatments.
Suppressor of Lin-12-like protein (C. elegans)
(SEL1L) is a component of the unfolded protein
response/endoplasmic reticulum-associated degrada-
tion (UPR/ERAD) pathway [3,4]. UPR/ERAD path-
way is the conserved protein quality-control
machinery of the ER that eliminates misfolded or
unassembled proteins via the cytosolic ubiquitin
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proteasome system (UPS). SEL1L is an ER-resident
transmembrane adaptor protein for the E3 ubiquitin
ligase hydroxymethylglutaryl reductase degradation
protein 1 (HRD1). Within the ER, the SEL1L-HRD1
complex is involved in the recruitment, retro-
translocation and ubiquitination of ERAD sub-
strates [5–7].
Besides being an adaptive response, the UPR/ERAD
pathway is triggered by cellular stress, hypoxia, reac-
tive oxygen species and nutrient deprivation, com-
monly present in the tumour microenvironment
(TME). Its constitutive activation has been described
in several human malignancies [8], but its precise role
is not fully clarified [9]. However, SEL1L is impli-
cated in tumour pathogenesis [10]. SEL1L functions
depend on tumour context being either down-
modulated in breast and pancreatic cancer [11,12], or
up-modulated in prostate, lung and cervical cancers
[13–15], including metastasis [16]. In colorectal can-
cer, SEL1L is up-regulated in the initial phases of neo-
plastic transformation, suggesting a potential function
in tumour initiation and progression [17]. In gliomas,
SEL1L protein expression significantly increases with
malignancy [18]. Increased UPR activation, which cor-
relates with tumour aggressiveness, has recently been
observed in GB patients [19] where a single nucleotide
polymorphism (rs12435998 within intron 3) conditions
survival and response to TMZ-based RT-CHT [20].
Besides tumours, SEL1L participates in normal neu-
rogenesis and in neurodegenerative diseases [10]. It is
involved in cell-matrix interactions during neuro-
genesis, promotes cell cycle accumulation in G1 phase
[21] and maintenance of a neural progenitor status and
lineage determination [22]. SEL1L also contributes to
CNS differentiation and vasculogenesis by modulating
Notch signalling [23,24]. UPR/ERAD and UPS path-
ways are significantly involved in regulating vascular
smooth muscle (SM) cell plasticity, survival and phe-
notype [25]. Murine SEL1L (mSEL-1L) was shown to
be expressed during CNS development [26] and its
deficiency led to severe multi-organ defects including
brain [27]. mSEL-1L was also shown to have an
essential function in guaranteeing the balance between
self-renewal and differentiation in neural progenitors
[22], possibly by controlling self-renewal and fate
determinant regulators [18,22].
This study aimed to investigate SEL1L expression
in 110 adult human gliomas of different molecular
subtype and grade using healthy nervous tissue as con-
trol. Here, we analysed the relationship of SEL1L with
(1) tumour progression and cell proliferation, in asso-
ciation with TME; (2) stemness potential; (3) prognos-
tic genetic and epigenetic markers (IDH1/2, TERT
promoter and TP53 mutations, EGFR gene amplifica-
tion, MGMT promoter hypermethylation, 1p/19q co-
deletion, ATRX status, LOH on 9p, 10q and 17p); and
(4) patient survival and response to therapy.
Materials and methods
Brain tumour specimens
A total of 110 adult glioma specimens were retrospec-
tively collected from the archives of the Research
Center/Policlinico di Monza Foundation (Vercelli,
Italy) (see supplementary material, Table S1). Patients
underwent partial or total resection at different Italian
Neurosurgery Units. Surgical tumour samples were
formalin fixed, paraffin embedded (FFPE) and cut in
5 μm-thick sections. The histological diagnosis was in
agreement with the current WHO guidelines [1]. IDH-
mutant tumours with retained nuclear ATRX expres-
sion and classic oligodendroglial histology but with
absence of total 1p/19q co-deletion were classified as
not otherwise specified (NOS) oligodendrogliomas [1].
Healthy nervous tissue was obtained from brain
autopsy of patients who died for vascular
encephalopathies.
Human cell lines (fetal cortex CB660 and GB-
derived GliNS2 and G144) were provided by ISENET
Biobanking (Milan, Italy, www.isenet.it).
Ethics statement
Human brain specimens were used in compliance with
the ethical human subject principles of the World
Medical Association Declaration of Helsinki Research.
Written informed consent was obtained from patients
after Institutional Ethics Committee approval.
Patient stratification
Survival data were available for a subgroup of
58 patients and clinical follow-up (FU) for 44 of them
(18 low-grade gliomas [LGGs] and 26 GBs). Twenty-
two IDH-WT GBs received post-operative fractionated
RT (60 Gy total dose; 2 Gy × 5 days/week for
6 weeks) with concomitant CHT with TMZ
(75 mg/m2/daily × 7 days/week for 6 weeks) followed
by adjuvant TMZ (200 mg/m2 × 5 days/week every
4 weeks for 6–12 cycles) according to the EORT-
NCIC protocol regimen published by Stupp et al [2].
Two GBs received only RT, whereas 2 cases only
TMZ. Among diffuse gliomas, 1 IDH-WT and 3 IDH-
mutant astrocytomas, 1 IDH-mutant/1p19q-codel and
4 NOS oligodendrogliomas were treated according to
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Stupp’s protocol. The same regimen was applied to
anaplastic oligodendrogliomas (2 IDH-mutant/1p19q-
codel and 1 NOS). TMZ alone was administered
to 4 diffuse IDH-mutant astrocytomas and 2 NOS
oligodendrogliomas. Patients with a Karnofsky perfor-
mance score < 60 received best supportive care.
SEL1L silencing by short interference
For silencing experiments, the human fetal CB660 cell
line (1 × 106 cells) was transiently nucleofected with
100 pmol small interference RNA (siRNA) against the
50 end of the SEL1L coding sequence and non-
targeting siRNA (NT siRNA) (Ambion, Life Technol-
ogies, Monza, Italy) using the Nucleofector® and
Amaxa nucleofector kit V (Lonza, Basel, Switzerland).
Scrambled siRNAs were used in order to guarantee
minimal or no off-target activity and the reliability of
the silenced phenotype.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using a
Ventana Full BenchMark® XT automated immuno-
stainer (Ventana Medical Systems Inc., Tucson, AZ,
USA) and the ultraView™ Universal DAB Detection
Kit (Ventana Medical Systems Inc.) as detection sys-
tem. Heat-induced epitope retrieval was obtained with
Tris–EDTA, pH 8. Negative controls were obtained by
omission of the primary antibody. Primary antibodies
are listed in supplementary material, Table S2.
Double immunostaining for SEL1L/Ki-67/MIB-1,
SEL1L/GFAP, SEL1L/IDH1R132H, SEL1L/Iba-1,
SEL1L/CD163, ATRX/Iba-1 and CD34/SEL1L was
performed using ultraView™ Universal Alkaline Phos-
phatase Red Detection Kit (Ventana Medical Sys-
tems Inc.).
Two overlapping antibodies against the N-terminal
region of SEL1L were used: a mouse monoclonal
(MSel1) antibody (amino acids 1–285, exons 1–8) [28]
and a rabbit polyclonal antibody (amino acids
159–186, exons 4–5) (#PA5-24179, Thermo Fisher
Scientific Inc., Walthman, MA, USA). Immunoreactiv-
ity was evaluated using a semi-quantitative system for
the percentage of positive cells and the staining inten-
sity in 5 randomly selected microscopic high power
fields (HPF) at ×400 magnification per tumour section.
The staining extent was scored as 0 (<1%), 1 (1–25%),
2 (26–49%), 3 (50–74%) and 4 (≥75%) according to
the percentage of positive cells. The staining intensity
was classified into four grades: 0, absence of immu-
noreaction; 1, weak staining; 2, moderate positivity;
3, strong reactivity. In particular, we considered the
nuclear (N), cytoplasmic (C) and total staining (N + C)
of tumour cells. All cases were evaluated independently
by 2 experienced pathologists (DS and RB). SEL1L+
glioma-associated microglia/macrophages (GAMs) and
myeloid cells were excluded from cell counts.
IHC for ATRX was used as surrogate marker for
the mutation status of the ATRX gene.
Protein extraction and Western blotting
Whole protein extracts from cell lines were isolated as
reported [18]. They were resolved by 10% SDS-PAGE,
transferred on PVDF membranes and probed with
MSel1 anti-SEL1L [28] and anti-Vinculin specific anti-
bodies (Sigma Aldrich Co., St. Louis, MO, USA) using
X-BlotP100 as hybridisation chamber (www.isenet.it).
Proteins were detected by ECL assay (Genespin, Milan,
Italy) and quantified using Scion Image program
(www.scioncorp.com). Data were expressed as aver-
ages of three independent experiments.
Subcellular protein fractions of cell lines were
obtained using the Subcellular Protein Fractionation
Kit (Pierce Biotechnology, Rockford, IL, USA). Anti-
α-tubulin and anti-Sox2 antibodies (Millipore, Burling-
ton, MA, USA) were used as controls for the cytosolic
and nuclear fractions, respectively.
Molecular genetics
Genomic DNA (gDNA) from FFPE tumour samples
was isolated using the QIAamp DNA Mini Kit
(Qiagen NV, Venlo, The Netherlands).
Search for mutations in IDH1 (exon 4) (GenBank
sequence NM_005896), IDH2 (exon 4) (GenBank
sequence NM_002168), TERT gene promoter region
(GenBank accession no. NM_198253) and TP53
(exons 4–8) genes (GenBank sequence NM_000546)
was performed by Sanger direct sequencing on an
ABI® 3130 Genetic Analyzer (Thermo Fisher Scien-
tific Inc.) [29]. Sequence variant nomenclature was in
agreement with the current Human Genome Variation
Society guidelines (http://varnomen.hgvs.org/).
The 1p/19q chromosomal status was assessed by
multiplex ligation-dependent probe amplification
(MLPA) using the SALSA-MLPA Kit P088-C2
(MRC-Holland, The Netherlands) [30].
Allelic imbalances on 9p, 10q and 17p chromosomes
were detected by loss of heterozygosity (LOH) analysis
and fragment analysis [31]. The EGFR gene amplifica-
tion status (GenBank accession no. NM_005228) was
assessed as described [31].
Quantitative methylation specific-PCR (qMS-PCR)
followed by capillary electrophoresis was used to
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determine the MGMT promoter hypermethylation sta-
tus (GenBank accession no. NM_002412) [32].
Statistical methods
Associations between categorical variables were evalu-
ated using 2 × 2 contingency tables by the two-tailed
Fisher’s exact test. The Pearson’s correlation coeffi-
cient was used to analyse the relationship between
SEL1L immunoreactivity and Ki-67/MIB-1 LI.
OS was defined as the time between histological
diagnosis and patient death or last FU. Patient alive at
last FU were considered as censored events. Survival
curves were estimated using the Kaplan–Meier method
and differences among groups were compared by the
log-rank test (Mantel–Cox). For survival analysis,
cases were dichotomised into the following categories:
low-SEL1L expression cases (≤25% positive tumour
cells, grades 0 and 1) and high-SEL1L expression
cases (>25% positive tumour cells, grades 2–4).
Analysis was carried out by SPSS v24.0 software
(SPSS Inc., Chicago, IL, USA). P values <0.05 were
considered as statistically significant.
Results
SEL1L silencing by siRNA
SEL1L silencing experiments on the human fetal
CB660 cell line confirmed that SEL1L codes for at
least three variants (AceView, http://www.ncbi.nlm.
nih.gov/IEB/Research/Acembly/) (see supplementary
material, Figure S1A–C). siRNA on SEL1L exon
12 and scrambled control (C) (panel A) showed the
down-modulation of the different SEL1L variants:
100 kDa isoform, corresponding to the ER-resident
variant SEL1LA (SEL1LA-p100), 70/78 kDa isoform
(SEL1L-p70/80) with a predominant nuclear location,
and 38 kDa secreted variant (SEL1L-p38), generally
expressed in tumour cells. Quantitative protein levels
(panel B) from WB analysis indicated the decrease of
the three isoforms compared to untreated (WT) and
scrambled (C) samples. The nuclear localisation of the
SEL1L-p70/80 variant was revealed by the
#PA5-24179 antibody (panel C) upon protein subcel-
lular fractionation.
SEL1L expression in healthy nervous tissue
Cerebral cortex and white matter
The MSel1 antibody revealed a granular reaction in the
cytoplasm of neurons and weakly positive cytoplasmic
and perinuclear staining of glial cells, including peri-
neuronal and perivascular oligodendroglial satellites
(see supplementary material, Figure S2A). Intense
nuclear immunostaining in glial cells and weak positiv-
ity in neurons were detected using the polyclonal
#PA5-24179 antibody (see supplementary material,
Figure S2B).
In the white matter, most perifascicular and per-
icapillary oligodendrocytes showed nuclear and mem-
branous immunopositivity with the MSel1 antibody
(see supplementary material, Figure S2C). Ischaemic
neurons showed enhanced immunoreactivity in their
cytoplasm [18]. The immunostaining intensity was
weaker with the polyclonal #PA5-24179 antibody (see
supplementary material, Figure S2D). The few
scattered ATRX+ nuclei corresponded to Iba1+ GAMs
(see supplementary material, Figure S2E), whereas
ATRX- nuclei to normal oligodendrocytes (see supple-
mentary material, Figure S2F).
Endothelial cells (ECs) of normal blood vessels and
capillaries did not reveal immunoreactivity with any of
the antibodies.
Cerebellum
The MSel1 antibody revealed a granular reaction in
the cytoplasm and dendrites of Purkinje cells (see sup-
plementary material, Figure S2G). Most granule cells
showed immunoreactivity in the nucleus, whereas glial
cells of the molecular layer and white matter were
weakly positive in the cytoplasm. The polyclonal
#PA5-24179 antibody showed weak cytoplasmic
immunostaining of Purkinje cells (see supplementary
material, Figure S2H). Some granule cells were vari-
ably and weakly positive in the nucleus. Glial cells of
the molecular layer and white matter were weakly pos-
itive in the nucleus.
Brain stem
SEL1L expression was confined to the ependymal
layer (in the nucleus and cytoplasm) with both
antibodies.
SEL1L expression in human gliomas
A total of 110 grade I–IV gliomas were studied using
both mono- and polyclonal anti-N-SEL1L antibodies.
SEL1L was expressed in the cytoplasm and/or in the
nucleus of tumour cells, according to the antibody
used, in GAMs and myeloid cells.
In diffuse astrocytomas, MSel1 antibody was
weakly and variably expressed in the cytoplasm and in
the perinuclear membrane of tumour cells (up to
15–20%) (Figure 1A). The few scattered SEL1L+ cells
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were identified as Iba-1+ GAMs (Figure 1B,C). In pil-
ocytic astrocytomas, SEL1L expression was never
detected with both antibodies (Figure 1D). In diffuse
ATRX+ oligodendrogliomas, no more than 5–10% of
tumour cells showed variably positive nuclear,
perinuclear and cytoplasmic staining (Figure 1E,F).
Typical honeycomb appearance and perineuronal satel-
lites variably showed either SEL1L+ or SEL1L− sta-
ined nuclei (Figure 1G,H). Neurons, intermingled with
tumour parenchyma or in infiltration areas, and GAMs
expressed SEL1L (Figure 1I,J).
In anaplastic gliomas, the frequency of SEL1L+
tumour cells ranged from >25 to 70–80% as did the
immunostaining intensity, with a predominant nuclear
staining (Figure 2A–F). In GBs, diffuse and variable
SEL1L immunoreactivity was found roughly in 100%
tumour cells (Figure 2G–I) in the cytoplasm and/or in
the nucleus, in relation to the antibody used. Hyper-
proliferative and hyperangiogenic areas, perinecrotic
pseudopalisades (Figure 2J) and the inner layer of
perivascular cuffings of co-option areas displayed the
highest SEL1L LI. In these areas, SEL1L+ tumour
Figure 1. Immunohistochemistry in low-grade gliomas using the monoclonal anti-SEL1L antibody. (A) Diffuse astrocytoma, SEL1LA+
microglia/macrophages; DAB, original magnification (OM) × 200. (B) Diffuse astrocytoma, Iba-1+ microglia/macrophages; DAB,
OM × 200. (C) Diffuse astrocytoma, ATRX- tumour cells and ATRX+ microglia/macrophages; DAB, OM × 200. (D) Pilocytic astrocytoma,
SEL1LA+ microglia/macrophages; DAB, OM × 200. (E) Diffuse oligodendroglioma, ATRX+ tumour cells and ATRX+ micro-
glia/macrophages; DAB, OM × 200. (F) Diffuse oligodendroglioma with honeycomb appearance, SEL1LA+ and SEL1LA- tumour cells;
DAB, OM × 200. (G) and (H) Diffuse oligodendroglioma with honeycomb appearance, SEL1LA+ (G) and SEL1LA− (H) perineuronal satel-
lites; DAB, OM × 400. (I) Perineuronal satellites, IDH1R132H+ tumour cells and SEL1LA+ neurons; double immunohistochemistry with
DAB and Alkaline Phosphatase Red, respectively, OM × 200. (J) Perineuronal satellites, oligodendroglial infiltration, SEL1LA+ neurons
and microglia/macrophages; DAB, OM × 200. DAB, 3,30-diaminobenzidine.
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Figure 2. Immunohistochemistry in malignant gliomas with monoclonal and polyclonal anti-SEL1L antibodies. (A) Anaplastic astrocy-
toma, SEL1LA+ neurons, microglia/macrophages and mostly tumour cells; DAB, original magnification (OM) × 200. (B) Anaplastic astro-
cytoma, SEL1L-p70/80+ neurons, microglia/macrophages and mostly tumour cells; DAB, OM × 200. (C) Anaplastic oligodendroglioma,
SEL1LA+ tumour cells in the cytoplasm and nucleus; DAB, OM × 200. (D) Anaplastic oligodendroglioma, SEL1L-p70/80+ tumour cells in
the nucleus; DAB, OM × 200. (E) Anaplastic oligodendroglioma, SEL1LA+ tumour cells; DAB, OM × 200. (F) Anaplastic
oligodendroglioma, Ki-67/MIB-1+ cells; DAB, OM × 200. (G) GB, H&E; DAB, OM × 400. (H) GB, SEL1LA+ tumour cells in the cytoplasm
and nuclei; DAB, OM × 400; (I) GB, SEL1L-p70/80+ tumour cells in the nucleus; DAB, OM × 400. (J) GB, SEL1L-p70/80+ tumour and
myeloid cells around a perinecrotic pseudopalisade; DAB, OM × 200. (K) GB, Nestin+ tumour cells; DAB, OM × 400. (L) GB, Sox2+
tumour cells; DAB, OM × 400. (M) GB, Ki-67/MIB-1+ cells; DAB, OM × 400. DAB, 3,30-diaminobenzidine.
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cells corresponded to Nestin+ and Sox2+ cells
(Figure 2K,L). The more intense nuclear immuno-
staining, revealed by the polyclonal #PA5-24179 anti-
body, corresponded to Ki-67/MIB-1+ nuclei and to
mitoses (Figure 2M). The diffuse background staining
in GBs could be related to the secreted variant
SEL1L-p38.
The immunostaining pattern detected by the poly-
clonal #PA5-24179 antibody was mainly nuclear in all
molecular subtypes.
Reactive astrocytes displayed weak cytoplasmic
SEL1L expression.
Relationship of SEL1L expression with tumour neo-
vasculature
SEL1L was not expressed in ECs and vascular peri-
cytes of normal blood vessels or quiescent tumour
blood vessels of both LGGs and high-grade gliomas
(HGGs). Conversely, ECs and vascular pericytes of
neo-formed proliferated tumour vessels (MVPs and
glomeruli) intensely expressed SEL1L in the nucleus
and cytoplasm (Figure 3A,B). Vascular pericytes were
revealed by α-smooth muscle actin (α-SMA) and neu-
ron glial antigen 2/chondroitin sulphate proteoglycan
4 (NG2/CSPG4) immunostaining (Figure 3C,D).
Relationship of SEL1L expression with GAMs
GAMs, as revealed by Iba-1, CD68 and CD163 immu-
nostaining, showed a similar distribution and fre-
quency in LGGs and HGGs. Whereas Iba-1+/CD163-
cells prevailed in the former, CD163+ cells were prev-
alent in the latter.
GAMs showed positive cytoplasmic and nuclear
immunostaining using the MSel1 antibody, as detected
by double immunostaining for SEL1L/Iba-1/CD68/
CD163. In LGGs, microglia cells corresponded to
scattered SEL1L+ cells (Figure 3E–I). In HGGs, the
diffuse SEL1L+ staining in hyperproliferative areas
overlapped the expression of GAMs and Ki-67/MIB-1
+ nuclei. In GBs, parenchymal tumour areas enriched
in Iba-1+/CD163+ cells were also enriched in SEL1L+
cells (Figure 3J,K). Peri- and intravascular macro-
phages were intensely SEL1L+ in the nucleus
(Figure 3L).
Molecular genetics
TERT promoter mutation was detected in 34 of
56 (60.7%) gliomas. The mutation rate was 26 of
31 (83.9%) in IDH-WT GBs and 8 of 25 (32%) in
LGGs. The point mutation c.−124C>T (C228T)
accounted for 24 of 34 (70.6%) and the c.−146C>T
(C250T) mutation for 10 of 34 (29.4%).
Point mutations at codon Arg132 of the IDH1 gene
were identified in 21 of 62 (33.9%) gliomas. The mis-
sense mutation c.395G>A (p.Arg132His) accounted
for 19 of 21 (90.5%), c.394C>A (p.Arg132Ser) and
c.394C>G (p.Arg132Gly) for 1 of 21 (4.8%) each. No
mutation was detected in the IDH2 gene at codon
Arg172.
The mutation rate of the TP53 gene in astrocytic gli-
omas was 9 of 43 (20.9%), 4 of them showing LOH
on the chromosome arm 17p. All mutations were
somatic changes.
MGMT promoter hypermethylation was detected by
MS-qPCR in 19 of 43 (44.2%) tumours. EGFR gene
amplification occurred in 19 of 60 (31.7%) gliomas.
Malignant gliomas showed LOH on 10q in 16 of
18 (88.9%) cases and LOH on 9p in 8 of 18 (44.4%)
cases. LOH on 17p was detected in 4 of 17 (23.5%)
astrocytic gliomas.
Finally, IDH-WT GBs, oligodendroglial tumours
and pilocytic astrocytomas all retained ATRX protein
expression in the nucleus. Conversely, it was lost in
10 of 12 (83.3%) astrocytic LGGs and in the IDH-
mutant GB.
Associations with clinical and molecular features
SEL1L immunoreactivity assessed by the MSel1 anti-
body was significantly associated with histological
malignancy grade (p = 0.002). Nuclei with the highest
SEL1L staining intensity statistically matched, in terms
of distribution, Ki-67/MIB-1+ nuclei (Pearson correla-
tion coefficient ρ = 0.797, p = 0.0001) (Figure 4).
No significant associations were found with patient
age, gender or anatomical location.
SEL1L immunoreactivity was significantly associ-
ated with TERT promoter mutation (p = 0.0001), EGFR
gene amplification (p = 0.0013), LOH on 10q
(p = 0.0012) and (borderline) with LOH on 9p
(p = 0.0546). Conversely, SEL1L overexpression was
mutually exclusive with the presence of IDH1/2 muta-
tions (p = 0.0001) (see supplementary material,
Table S3).
Survival analysis
The relationship between SEL1L protein expression
and OS was analysed in a subgroup of 58 patients,
including 2 pilocytic astrocytomas, 20 diffuse and
6 anaplastic gliomas, and 30 GBs. By Kaplan–Meier
survival analysis, SEL1L immunoreactivity was signif-
icantly associated with a worse prognosis (p = 0.0001)
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Figure 3. Immunohistochemistry using monoclonal and polyclonal anti-SEL1L antibodies with regard to tumour neo-vasculature and
GAMs. (A) GB with proliferated tumour blood vessels, SEL1LA+ ECs and vascular pericytes; DAB, original magnification (OM) × 200.
(B) GB with proliferated tumour blood vessels, SEL1L-p70/80+ ECs and pericytes; DAB, OM × 200. (C) GB with proliferated tumour blood
vessels, SEL1LA+ and α-SM-Actin+ vascular pericytes; double immunohistochemistry with DAB and Alkaline Phosphatase Red, respec-
tively, OM 200×. (D) GB with proliferated tumour blood vessels, NG2/CSPG4+ ECs and pericytes; DAB, OM × 200. (E) Diffuse astrocy-
toma, Iba-1+ GAMs; DAB, OM × 200. (F) Pilocytic astrocytoma, Iba-1+ GAMs; DAB, OM × 200. (G) Diffuse oliodendroglioma, Iba-1+
GAMs; DAB, OM × 200. (H) Anaplastic astrocytoma, Iba-1+ GAMs; DAB, OM × 200. (I) Anaplastic oligodendroglioma, Iba-1+ GAMs;
DAB, OM × 200. (J) GB, Iba-1+ scattered macrophages in tumour parenchyma; DAB, OM × 200. (K) GB, SEL1LA+ scattered macrophages
in tumour parenchyma; DAB, OM × 200. (L) GB, SEL1L-p70/80+ peri- and intravascular macrophages; DAB, OM × 200. DAB, 3,30-
diaminobenzidine.
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(Figure 5A). The median survival time was
130 months for cases with low-SEL1L expression and
13 months for cases with high-SEL1L expression.
Censored cases were 12 of 20 (60%) for the former
and 4 of 38 (10.5%) for the latter. Moreover, in the
subgroup of 44 patients with recorded FU, SEL1L
overexpression conditioned a poor response to the
post-surgical therapy (p = 0.038) (Figure 5B).
Discussion
In human malignancies, SEL1L plays either an onco-
genic or a tumour suppressive role according to the
cellular context or the isoform predominance. At the
protein level, SEL1L may have a double cellular loca-
tion (nucleus and cytoplasm) possibly related to its
variable response to genotoxic insults [14,17]. In the
present series of gliomas, SEL1L cellular location was
assessed using two overlapping antibodies against the
N-terminal region of the protein that revealed different
variants. The detection of the cytoplasmic variant pre-
vailed over the nuclear variant using the MSel1 anti-
body, whereas the #PA5-24179 antibody mainly
revealed the latter. The subcellular location corre-
sponds to three variants demonstrated by siRNA
experiments on the human fetal CB660 cell line and
on GB-derived cell lines (as described in AceView)
[33]. The diffuse background reaction in GB speci-
mens observed using both antibodies may be ascribed
to the secreted variant SEL1L-p38 [33]. The cytoplas-
mic and nuclear variants may exert the same biological
function in different cellular compartments. The func-
tion of SEL1LA-p100 could predominate in the cyto-
plasmic UPR/ERAD/UPS pathway in response to the
exposure of tumour cells to intrinsic (genomic instabil-
ity, oncogene expression and increased metabolic bur-
den) and extrinsic (hypoxia, oxidative stress and
nutrient deprivation) stresses within the TME. On the
other hand, the nuclear SEL1L-p70/80 variant might
be involved in the maintenance of nuclear proteostasis
in order to preserve the nuclear UPS from stress-
induced dysfunction [34]. As a matter of fact, the
SEL1L gene contains a nuclear localisation signal at
the N-terminal region of the protein [33]. The presence
of distinct proteostasis circuits, which cooperate in the
quality control of proteins between nucleus and cyto-
plasm, has recently been reported [35–38]. A recent
Figure 4. Correlation between SEL1L and Ki-67/MIB-1 LIs. Linear
regression analysis between SEL1L immunoreactivity and Ki-67/
MIB-1 LI (ρ = 0.797, p = 0.0001).
Figure 5. Relationship between SEL1L expression and survival in glioma patients. (A) Kaplan–Meier survival curves for OS in 58 glioma
patients with respect to SEL1L immunoreactivity using the MSel1 antibody. (B) Kaplan–Meier survival curves for OS in 44 glioma
patients after patient stratification for post-surgical treatment.
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study also revealed a specific role for the ubiquitin-like
molecule NEDD8 in the defense mechanism against
proteotoxic stess [39].
In healthy cerebral cortex and white matter, SEL1L
is expressed in neurons and glial cells. In the cerebel-
lum it is detected in cells of the molecular layer and in
Purkinje cells. In brain stem, SEL1L is expressed in
cells of the ependymal layer. The variable expression
in normal oligodendrocytes of the white matter, peri-
neuronal satellites and cerebellum granule cells may
be related to their different functional status.
Our findings in gliomas are based on the immuno-
histochemical detection of SEL1L with both anti-
bodies. The interpretation of the immunostaining
should take into account the dual meaning of SEL1L,
as a marker associated with either tumour progression
or cell differentiation. Whereas SEL1L is not
expressed or barely detectable in LGGs, HGGs exhibit
significantly increased immunoreactivity, in terms of
number of positive cells and reaction intensity. In
GBs, SEL1L expression displays the highest LI in
hyperproliferative areas, correlating with cell prolifera-
tion (Ki-67/MIB-1) and mitotic indices. In these areas,
SEL1L immunostaining corresponds to the positivity
of stemness markers, such as Nestin and Sox2. This
finding is even more evident with the polyclonal anti-
body, which mainly reveals the nuclear immunoreac-
tivity. In GBs, the cytoplasmic and nuclear staining
varies consistently with the heterogeneous presence of
undifferentiated and regressive areas. Hyper-
proliferative areas of GB are composed of GB stem
cells (GSCs) or progenitors at variable differentiation
stages [40–43]. In our opinion, GSCs and progenitors
represent a functional status regulated by the TME
[43–46] rather than a cell type [43]. This hypothesis is
supported by the variable SEL1L expression observed
in GB-derived human cell lines (I. Biunno,
unpublished data). On the other hand, SEL1L might
contribute to tumour growth and resistance to ther-
apy [47].
The weak immunoreactivity in the cytoplasm of
reactive astrocytes revealed by the MSel1 antibody is
in line with the differentiation potential of SEL1L and
the poor positivity of astroglia in the healthy nervous
tissue.
The constitutive SEL1L expression in GAMs ham-
pers the evaluation of its expression from tumour cells.
In HGGs, GAMs are mainly Iba-1+/CD163
+/CD45high, that is, corresponding to blood-borne
macrophages. In LGGs and in infiltration areas of
HGGs, Iba-1+/CD163-/CD45low GAMs prevail as
reactive ramified microglia deriving from resident
microglia [48,49]. As the frequency of GAMs is
similar in LGGs and HGGs, the increased SEL1L
expression in the latter can be attributed to the
increased number of SEL1L+ tumour cells and to their
staining intensity. The debated question on GAMs,
that is, if they are ‘friends or foes’ in respect to the
tumour, has been solved, considering GAMs as
favouring tumour progression [48–51]. However,
uncertainties still remain, mainly in relation to the
timing of the blood–brain barrier disruption and the
origin of GAMs [48,49,52]. As a matter of fact, the
scattered SEL1L+ cells in pilocytic astrocytoma corre-
spond to Iba-1+ GAMs.
SEL1L is not detected in ECs of normal or quies-
cent tumour blood vessels, but it is strongly expressed
by ECs and vascular pericytes of the proliferative
tumour neo-vasculature in malignant gliomas (micro-
vascular proliferations and glomeruli). This is of par-
ticular importance with reference to pericytes because
SEL1L influences development of the vascular net-
work during embryogenesis and pericyte plasticity
[23,24]. SEL1L detection in pericytes may be attrib-
uted to its expression by GSCs within the perivascular
niche [53–56].
In the present study, SEL1L overexpression associ-
ates significantly with TERT promoter mutation,
EGFR gene amplification, LOH on 10q and (border-
line) 9p chromosomes, all well-known negative prog-
nostic markers for gliomas. By contrast, SEL1L
correlates inversely with IDH1/2 mutations that are
the most relevant prognostic marker. As the above
mentioned genetic profile is commonly detected in
the molecular subgroup of IDH-WT GBs, SEL1L
may be suggested as a new potential biomarker for
these tumours.
In agreement with the above findings, SEL1L over-
expression conditions an unfavourable prognosis in
glioma patients and a worse response to TMZ-based
RT-CHT. As a matter of fact, current therapeutic treat-
ments for GB patients induce ER proteostasis imbal-
ance that might, ultimately, contribute to the selection
of an adapted cell population that is resistant to the ini-
tial treatment [57]. In line with our results, SEL1L is
an important mediator for TMZ resistance and a poor
prognostic factor for GB patients [58]. Recently, using
a CRISPR-Cas9 approach in GB-derived cell lines,
actionable pathways including regulator of stemness
and stress response (ufmylation and ERAD pathways)
have been identified as responsible for tumour growth
and TMZ sensitivity [59]. In particular, SEL1L and
HRD1 were among the highly ranked GB-specific fit-
ness genes in GSCs emphasising the relevance of
proteostasis gene networks as a potential therapeutic
strategy for GB.
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All these findings support the involvement of
SEL1L, as a member of the ER protein quality-control
machinery, in glioma progression, neo-angiogenesis
affecting TME (both immune cells and ECs), and in
modulating efficacy of therapies.
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